Insider Buying: Charles Theuer Acquires 50,000 Shares of 4D Molecular Therapeutics

Charles Theuer, an insider at 4D Molecular Therapeutics, Inc. (NasdaqGS: FDMT), purchased 50,000 shares of the company on June 17, 2026. This transaction was not part of a pre-planned purchase program.

Insider Buying and Selling at 4D Molecular Therapeutics, Inc.

On June 17, 2026, several insiders at 4D Molecular Therapeutics made significant stock purchases. Charles Theuer bought 50,000 shares, as did Glenn Sblendorio, Susannah Gray, Jacob Chacko, and Nancy Miller-Rich. John Milligan acquired 75,000 shares. None of these transactions were pre-planned.

Other Institutional Activity in 4D Molecular Therapeutics

Institutional investors have also been active in 4D Molecular Therapeutics. Janus Henderson Group PLC increased its holdings by 611,276 shares to a total of 5,247,151 shares, valued at approximately $48.9 million. RA Capital Management, L.P. reduced its stake by 603,432 shares, holding 5,049,779 shares worth about $47 million. Goldman Sachs Group Inc. trimmed its position by 97,467 shares, ending with 4,205,438 shares valued at $39.2 million. BlackRock, Inc. added 80,427 shares, bringing its total to 4,145,303 shares, valued at around $38.6 million.

4D Molecular Therapeutics, Inc. Stock Down 34.2%

Shares of 4D Molecular Therapeutics (NasdaqGS: FDMT) traded near $9.66 on Friday. The company has a market cap of approximately $505 million. It is currently not profitable, hence it has no meaningful P/E ratio, but it has a forward P/E of -2.59. The stock's beta is 2.756, indicating higher volatility compared to the market. Over the past 52 weeks, the stock has ranged between $3.68 and $12.34, with a 50-day moving average of $9.43 and a 200-day moving average of $9.24.

Recent Earnings

In its recent earnings report, 4D Molecular Therapeutics posted revenue of $88.24 million, with a remarkable revenue growth of 216.6%. Despite this growth, the company reported a net margin of -182.34% and a return on equity of -34.92%. The next earnings report is expected on August 10, 2026.

Analysts Set New Price Targets

Analysts have shown optimism towards 4D Molecular Therapeutics. On March 30, 2026, Jefferies assumed coverage with a buy rating and a $21 price target. HC Wainwright & Co. reiterated their buy rating with a $36 target on March 20, 2026. RBC Capital maintained a buy rating, setting a $35 target on March 19. The consensus among nine analysts is a buy rating, with a mean target price of $28.22.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc. is a biotechnology company based in Emeryville, California. Founded in 2013, it focuses on developing adeno-associated virus vectors for gene therapy using its proprietary platform, Therapeutic Vector Evolution. The company is advancing several product candidates, including 4D-150 for retinal diseases and 4D-710 for cystic fibrosis. The company collaborates with Otsuka Pharmaceutical Co., Ltd. Dr. David H. Kirn serves as CEO, and the company employs 196 people.

Bottom Line

Charles Theuer's recent purchase of 50,000 shares of 4D Molecular Therapeutics underscores insider confidence in the company's future. Investors keep a close eye on insider buying as a potential indicator of a company's prospects. As with all 13F filings and insider transactions, the data reflects past actions and may not indicate current positions.